Shares of Achaogen Inc. (NASDAQ:AKAO) were down 4.4% on Tuesday . The stock traded as low as $3.67 and last traded at $3.70, with a volume of 168,540 shares changing hands. The stock had previously closed at $3.87.

Several analysts have weighed in on AKAO shares. Zacks Investment Research raised Achaogen from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a research note on Friday, March 18th. Needham & Company LLC reissued a “hold” rating on shares of Achaogen in a research note on Monday, May 9th. Cowen and Company downgraded Achaogen from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 31st. Finally, Wedbush reissued a “neutral” rating and issued a $7.00 price objective on shares of Achaogen in a research note on Friday, May 6th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $10.63.

The stock’s market cap is $67.69 million. The company has a 50 day moving average price of $3.89 and a 200-day moving average price of $3.75.

Achaogen, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.